A Phase I/II Trial of Rucaparib in Combination With Ramucirumab With or Without Nivolumab in Previously Treated Patients With Advanced Gastric and Esophageal Adenocarcinoma (RiME)
Latest Information Update: 03 Feb 2023
At a glance
- Drugs Nivolumab (Primary) ; Ramucirumab (Primary) ; Rucaparib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms RiME
Most Recent Events
- 30 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 31 Jan 2022 Planned primary completion date changed from 1 Oct 2021 to 1 Oct 2022.
- 22 Jan 2022 Trial design presented at the 2022 Gastrointestinal Cancers Symposium